CAR-T therapy after stem cell transplant for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new treatment called CAR-T cell therapy given after your own stem cell transplant. It aims to improve the response for multiple myeloma, a type of blood cancer, and is for patients who did not get a complete response after initial chemo or who have high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a confirmed diagnosis of multiple myeloma.
- After your first 4 rounds of chemo, you had a partial response (tumor shrank but not gone) or a complete response (tumor gone) with high-risk factors.
- You are healthy enough for a stem cell transplant and have adequate liver and overall organ function.
- You do not have an active infection like HIV, hepatitis B or C, or tuberculosis.
- You are able to give written informed consent and are not pregnant or planning pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatments for newly diagnosed multiple myeloma: standard stem cell transplant (ASCT) alone versus ASCT followed by CAR-T cell therapy. CAR-T uses your own immune cells to target and kill myeloma cells, which may improve outcomes after transplant.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests a new type of CAR-T cell treatment for multiple myeloma that uses donor cells. It's for patients whose cancer came back or didn't fully respond to prior treatments.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.